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Background
We evaluated HIV antibody (Ab) responses elicited by
immunization, in a phase I/II placebo-controlled double
blind trial using multiclade, multigene HIV-1-DNA
prime boosted with HIV-MVA conducted among
healthy volunteers in Tanzania (HIVIS03).
Methods
Sixty HIV-uninfected volunteers, randomized into groups
of 20 received placebo or 1 mg HIV-DNA intradermally
(id) or 3.8 mg intramuscularly (im). DNA plasmids con-
taining HIV-1 gp160 subtypes A, B, C; rev B; p17/p24
gag A, B and RTmut B were given at months 0, 1 and 3
using a needle-free Biojector device. HIV-MVA expres-
sing CRF01_AE HIV-1 env, gag, pol was administered im
by needle at months 9 and 21. Sera were tested at base-
line, two months post-first and four weeks post-second
HIV-MVA boosting. HIV Ab responses were tested using
pseudoviruses and TZM-bl cells as well as luciferase-
expressing infectious molecular clones (IMC-LucR) in
PBMC-based assays. ADCC responses were tested using
the flow cytometry GranToxiLux-based assay.
Results
Neutralizing Ab activity was demonstrated only in the
PBMC assay, and after the second MVA boost in 24
(83%) of 29 vaccinees against the clade CRF01_AE
CM235 IMC and in 21 (72%) of 29 vaccinees against
clade B SF162-IMC. NK cell depletion from PBMC tar-
gets resulted in a significant loss of HIV inhibition by
vaccinee sera, indicating a role of Ab-mediated Fcg-recep-
tor function. Vaccine-induced ADCC responses were
detected in 21 (75%) of 28 vaccinees after the second
HIV-MVA boost. ADCC Ab titers did not differ signifi-
cantly between id- (median 840, range 300-5400) and im-
primed (median 880, range 400-3600) vaccinees (p=0.45).
Conclusion
HIV-DNA priming followed by two HIV-MVA boosts
elicited HIV-specific inhibitory and/or ADCC-mediating
antibody responses in a high proportion of Tanzanian
adults.
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